Scinai Immunotherapeutics (SCNI) Debt Ratio (2018 - 2026)

Scinai Immunotherapeutics (SCNI) posted Debt Ratio of 0.04 for Q1 2026, down 31.99% sequentially from 0.05 in Q4 2025.

Scinai Immunotherapeutics (SCNI) Debt Ratio (2018 - 2026) Analysis & Trends

Scinai Immunotherapeutics has reported Debt Ratio for 9 years, with the latest figure at 0.04 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04 (changed N/A YoY) and the FY2025 annual result came in at 0.05, up 5.36% from the prior year.
Debt Ratio slipped to 0.04 in Q1 2026 per SCNI's latest filing, from 0.05 in the prior quarter.
Over five years, Debt Ratio peaked at 1.36 in Q2 2024 and troughed at 0.04 in Q1 2026.
A 5-year average of 0.66 and a median of 0.78 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2024: Debt Ratio soared 77.2% in 2023, then slumped 95.5% in 2024.
Over 5 years, Debt Ratio stood at 0.76 in 2022, then soared by 49.62% to 1.13 in 2023, then plunged by 95.5% to 0.05 in 2024, then climbed by 5.36% to 0.05 in 2025, then slumped by 31.99% to 0.04 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.04, 0.05, and 0.07 for Q1 2026, Q4 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Scinai Immunotherapeutics	11.72 Mn	-3.10 Bn	-1.12 Mn	0.04

Download Data